Characteristics Associated to Lipodystrophy Syndrome among HIVInfected Patients Naive and on Antiretroviral Treatment
Carregando...
Data
2012
Tipo de documento
Artigo de Periodico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso aberto
Editora
Autores
Alencastro, Paulo Ricardo
Wolff, Fernando Hertz
Schuelter-Trevisol, Fabiana
Ikeda, Maria Letícia
Brandão, Ajácio Bandeira de Mello
Barcellos, Nêmora T.
Fuchs, Sandra Costa
Orientador
Coorientador
Resumo
Abstract
Background: HIV-associated lipodystrophy involves changes in complex metabolic networks that are associated
with increased cardiovascular risk. It has been associated with the use of combined antiretroviral treatment (cART),
particularly Protease Inhibitors (PI) and thymidine analogs. This study aims to evaluate characteristics and use of
ART associated with lipodystrophy, lipohypertrophy, and lipoatrophy among HIV-infected patients.
Methods: A cross-sectional study was conducted in HIV-infected patients of both genders, aged 18 years or
older, who sought care at an HIV/AIDS referral service for diagnostic confirmation or treatment between June 2006
and December 2008.
Results: 1240 out of 1295 patients with HIV infection were included. Among patients on cART, women had
a higher risk of lipohypertrophy than men, as well as a time since diagnosis of HIV greater than 6 years (versus
<3 years). For lipoatrophy, age, education, lifestyle, and body mass index were associated with increased risk.
Metabolic parameters were higher among patients on ART; and cART and PI use were independently associated
with lipohypertrophy, lipoatrophy and lipodystrophy. The use of PI can be regarded as responsible for 13% of the
association of ART and lipodystrophy, and of 11.5% for the thymidine analogs use, independent of gender, skin color,
smoking, CD4, and BMI.
Conclusions: Risk factors for lipodystrophy, lipoatrophy and lipohypertrophy are marked among ART users, but
also among ART naïve patients.
Palavras-chave
HIV, Lipodystrophy, Lipohypertrophy, Lipoatrophy, Risk factors, HAART, Dyslipidemia